Incyte Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Well, thank you, everyone, for joining us at our 2021 Goldman Sachs Healthcare Conference. I'm Salveen Richter, biotechnology analyst at Goldman Sachs. And we're pleased today to have Incyte Pharmaceuticals with us.
With us, we have Herve Hoppenot, Chairman, President and CEO; as well as Christiana Stamoulis, CFO.
With that, Herve, I'm going to turn it over to you to make any opening comments, and then we'll jump to questions.
Okay. So yes, good morning. Thank you for inviting us to present here.
So it's obviously a very busy time for Incyte, as we speak today. It was a very successful year in term of growth of revenue over the past 18 months. In 2020, Jakafi grew at 15% to $1.94 billion in the U.S., the rest of the hematology/oncology portfolio grew at 46%. The royalties we are getting from Tabrecta, ruxolitinib outside of the U.S. and baricitinib grew at 28% and reached our number
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
